Climb Bio
CLYM
10.71
+0.03
+0.28%
Climb Bio
US · CLYM
#3610 by market cap
Listed 2021
10.71
+0.03
+0.28%
Live - 5344 symbols - heartbeat 160s ago
· 2026-10-08 09:13
Pre-market
10.50
-1.96%
After-hours
10.71
0.00%
- Market cap
- 615.14M
- P/E (TTM)i
- -13.06
- P/Bi
- 2.57
- EPSi
- -0.88
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on CLYM?
Anonymous reader poll. Unscientific, not investment advice.
About Climb Bio
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The firm develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
- Founded
- 2018
- CEO
- Dr. Aoife M. Brennan, M.D.
- Employees
- 29
- Headquarters
- Wellesley Hills, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- climbbio.com
Company profile
- Exchange
- US
- Symbol
- CLYM
- Market-cap rank
- #3610
- Listing date
- 2021-08-10
- Market cap
- 615.14M
- Float cap
- 414.91M
- Shares out
- 57.44M
- Float shares
- 38.74M
Sectors & themes
Quote time 2026-10-08 09:13:14 · For reference only, not investment advice and not tailored to your situation.